Unique ID issued by UMIN | UMIN000017153 |
---|---|
Receipt number | R000019895 |
Scientific Title | A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 in advanced esophageal cancer patients with normal oral intake |
Date of disclosure of the study information | 2015/04/16 |
Last modified on | 2019/03/27 07:12:00 |
A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 in advanced esophageal cancer patients with normal oral intake
A phase II study of neoadjuvant chemotherapy with DCS for esophageal cancer
A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 in advanced esophageal cancer patients with normal oral intake
A phase II study of neoadjuvant chemotherapy with DCS for esophageal cancer
Japan |
esophageal cancer
Surgery in general | Gastrointestinal surgery |
Malignancy
NO
This phase II study is being conducted to determine the efficacy of neoadjuvant chemotherapy using docetaxel, cisplatin and S-1 (DCS) for stage IB/II/III esophageal cancer with normal oral intake
Efficacy
Exploratory
Phase II
Pathologocal response
Curative resection rate
Clinical response of chemotherapy
Toxicities of chemotherapy
Postoperative complication
2y survival rate
3y survival rate
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine |
Chemotherapy using Docetaxel+Cisplatin+S-1 followed by surgicalresection
20 | years-old | <= |
75 | years-old | >= |
Male and Female
(1) Patients must have historogic confirmation of squamous cell carcinoma or adenocarcinoma or basaloid carcinoma by endoscopic biopsy
(2) TMN stage IB/II/III
(3) 20 years and older, 75 years and younger
(4) ECOG performance status 0-1
(5) Patients have not received prior chemotherapy or radiotherapy
(6) Patients who are going to under curative esophagectomy (R0)
(7) Patients with normal oral intake
(8) Lavoratory values as fellows;
4000 < WBC < 12000/mm3
granulocyte count > 2000/mm3
Hemoglobin > 8.0 g/dL
Platelet count > 100,000/mm3
AST, ALT < 100 IU/L
T-bil < 1.5 mg/dL
Cr < 1.2 mg/dL
Ccr > 60 mL/min/body
(1)Patients with concurrent other primary cancer requiring treatment
(2)Pregnancy, possible pregnancy after delivery or breast feeding
(3)Patients requiring systemic administration of steroid
(4)Positive HBs antigen
(5)Patients requiring flucytosine or phenytoin or warfarine administration
(6)Patients for allergy of iodine
(7)Patient with allergic response to anticancer drugs (docetaxel, cisplatin, S-1)
(8)Severe peripheral nerve disorder
(9)Patients with interstitial pneumonia or pulmonary fibrosis
(10)Active infection
(11)Patients with a history of myocardial infarction or unstable angina pectoris within the previous six months
(12)Patients with uncontrolled hypertension or diabetes melitus
40
1st name | |
Middle name | |
Last name | Mikihito Nakamori |
Wakayama Medical University
Second Department of Surgery
811-1 Kimiidera, Wakayama, Japan
073-441-0613
chamcham@wakayama-med.ac.jp
1st name | |
Middle name | |
Last name | Mikihito Nakamori |
Wakayama Medical University
Second Department of Surgery
811-1 Kimiidera, Wakayama, Japan
073-441-0613
chamcham@wakayama-med.ac.jp
Second Department of Surgery, Wakayama Medical University
Second Department of Surgery, Wakayama Medical University
Self funding
NO
2015 | Year | 04 | Month | 16 | Day |
Unpublished
Completed
2014 | Year | 06 | Month | 20 | Day |
2014 | Year | 06 | Month | 10 | Day |
2014 | Year | 07 | Month | 01 | Day |
2019 | Year | 03 | Month | 27 | Day |
2015 | Year | 04 | Month | 16 | Day |
2019 | Year | 03 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019895